Indivior Statement Regarding State Attorney General's Recent Announcements Relating to SUBOXONE® (buprenorphine and naloxone) Film Litigation August 23 2022

Indivior is proud to be the global leader in developing medications to treat opioid use disorder. These evidence-based treatment options are a critical part of the solution to the global opioid crisis and we take our role as a responsible steward of these medications extremely seriously. Our leadership is focused on the responsible marketing practices of all our products, including those for addiction.

Indivior is also committed to ensuring our medication for opioid use disorder is affordable for patients by working with all public health programs and plans so that patient copay costs are as a low as $0. This is part of our effort to provide patients the access to opioid use disorder treatment they need for recovery.

We do not discuss ongoing litigation.

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.


Media Contacts:

US
IndiviorMediaContacts@indivior.com
+1 804-594-0836

UK
Tulchan Communications
+44 207-353-4200

Investor Contact:

Jason Thompson
Vice President, Investor Relations
Indivior PLC (LON: INDV)
Mobile: 804-402-7123

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Indivior plc published this content on 23 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 August 2022 21:07:03 UTC.